Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone in clinical practice.

K Rickels1

  • 1Department of Psychiatry, University of Pennsylvania, Philadelphia 19104.

The Journal of Clinical Psychiatry
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Buspirone, a nonbenzodiazepine anxiolytic, effectively treats generalized anxiety disorder with effects comparable to benzodiazepines but without dependency. It also shows antidepressant potential, particularly for mixed anxiety-depression symptoms.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Replication Of Symptom Distress Factors In Anxious Neurotic Outpatients.

Multivariate behavioral research·2016
Same author

Re: Over-the-counter drugs for the treatment of mood and anxiety disorders--the views of German pharmacists. By J. Hamann, K. Linde, H. D. Schweiger, O. Kusmakow, H. Foerstl, Pharmacopsychiatry 2014; 47: 84-88.

Pharmacopsychiatry·2014
Same author

Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder.

The pharmacogenomics journal·2012
Same author

Serotonin receptor 2A (HTR2A) gene polymorphism predicts treatment response to venlafaxine XR in generalized anxiety disorder.

The pharmacogenomics journal·2011
Same author

Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder.

The American journal of psychiatry·2001
Same author

Venlafaxine in the treatment of premenstrual dysphoric disorder.

Obstetrics and gynecology·2001
Same journal

Major Depressive Disorder and PTSD Treatment Outcome in Interpersonal Psychotherapy and Prolonged Exposure.

The Journal of clinical psychiatry·2026
Same journal

Psychiatrists and Medical Aid in Dying: Entering Uncharted Waters.

The Journal of clinical psychiatry·2026
Same journal

Mind and Metabolism in Crisis: US Mortality Involving Obesity and Psychiatric Disorders-Trends, Disparities, and ARIMA Projections.

The Journal of clinical psychiatry·2026
Same journal

Generative AI for the Clinical Psychopharmacologist: Is It Ready for Prime Time?

The Journal of clinical psychiatry·2026
Same journal

Posttrauma Benzodiazepine Use and Subsequent PTSD: A Population-Wide Analysis Following Extreme Traumatic Exposure.

The Journal of clinical psychiatry·2026
Same journal

The Challenges of PTSD Prevention: Placing Benzodiazepine Use in Context.

The Journal of clinical psychiatry·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Neuroscience

Background:

  • Buspirone is a novel nonbenzodiazepine anxiolytic and a selective 5-HT1A partial agonist.
  • It was the first medication of its class introduced for treating generalized anxiety disorder (GAD).

Purpose of the Study:

  • To review the efficacy and clinical applications of buspirone in treating anxiety and related disorders.
  • To compare buspirone's anxiolytic and antidepressant effects with existing treatments.

Main Methods:

  • Review of well-controlled clinical trials and patient studies.
  • Analysis of therapeutic outcomes in diverse patient populations.

Main Results:

  • Buspirone demonstrates anxiolytic efficacy similar to benzodiazepines and superior to placebo.

Related Experiment Videos

  • Antidepressant effects have been observed, making it suitable for mixed anxiety-depression symptoms.
  • It is particularly beneficial for generalized anxiety disorder, chronic anxiety, and the anxious elderly.

    • Conclusions:

    • Buspirone is a safe alternative to benzodiazepines, offering gradual anxiety relief without dependency.
    • Its utility in panic disorder remains inconclusive; further research is needed on its potential "curative" properties and impact on coping skills.